Qizheng Tibetan Medicine disclosed its 2026 semi-annual report on the evening of August 21. In the first half, it achieved operating revenue of 978 million yuan, and net profit attributable to shareholders of the listed company excluding non-recurring gains and losses of 300 million yuan, up 3.59% year on year. It also plans to distribute a cash dividend of 2.3 yuan per 10 shares, tax included, to all shareholders. Operating profit for the same period was 416 million yuan, and net profit attributable to shareholders of the listed company was 371 million yuan. Qizheng Tibetan Medicine is a leading modern Tibetan medicine enterprise. Its core product, Xiaotong Plaster, ranks first among external-use plasters in the skeletal and muscular system category of Chinese patent medicines, and its share of the Tibetan medicine market exceeds 50%.
Tibet Cheezheng Tibetan Medicine Co LtdFirst-half net profit up 3.59% and interim dividend proposed.
